Literature DB >> 22045163

Adalimumab treatment may replace or enhance the activity of steroids in steroid-refractory tuberculous meningitis.

Ho-Su Lee1, Yumi Lee, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Jun Hee Woo, Sung-Han Kim.   

Abstract

We describe a paradoxical response involving the central nervous system in a patient with steroid-refractory tuberculous meningitis that was unresponsive to systemic corticosteroids but was improved with adalimumab. The immunomodulatory effect of tumor necrosis factor inhibitors may have a role in replacing or enhancing the activity of steroids in the management of steroid-refractory tuberculous meningitis.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22045163     DOI： 10.1007/s10156-011-0334-y

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN： 1341-321X            Impact factor:   2.211


  11 in total

1.  A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.

Authors:  Denise C Hsu; Kimberly F Faldetta; Luxin Pei; Virginia Sheikh; Netanya S Utay; Gregg Roby; Adam Rupert; Anthony S Fauci; Irini Sereti
Journal:  Clin Infect Dis       Date:  2015-09-22       Impact factor: 9.079

2.  Intractable Tuberculous Meningitis With Paradoxical Reactions Treated by Anti-Tissue Necrosis Factor-α Therapy.

Authors:  Keon-Woo Kim; Hyo Jae Kim; Hyun-Woo Kim; Sung-Han Kim; Sang Ahm Lee; Yong Seo Koo
Journal:  Neurol Clin Pract       Date:  2021-08

Review 3.  Paradoxical manifestations during tuberculous meningitis treatment among HIV-negative patients: a retrospective descriptive study and literature review.

Authors:  Rogelio Domínguez-Moreno; Miguel García-Grimshaw; David Medina-Julio; Carlos Cantú-Brito; Alejandra González-Duarte
Journal:  Neurol Sci       Date:  2021-10-27       Impact factor: 3.830

Review 4.  HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome.

Authors:  Rachel P J Lai; Graeme Meintjes; Robert J Wilkinson
Journal:  Semin Immunopathol       Date:  2015-09-30       Impact factor: 9.623

5.  Adalimumab for Corticosteroid and Infliximab-Resistant Immune Reconstitution Inflammatory Syndrome in the Setting of TB/HIV Coinfection.

Authors:  Nilar Lwin; Michael Boyle; Joshua S Davis
Journal:  Open Forum Infect Dis       Date:  2018-01-30       Impact factor: 3.835

6.  Late-onset paradoxical reactions 10 years after treatment for tuberculous meningitis in an HIV-negative patient: a case report.

Authors:  Akira Machida; Tasuku Ishihara; Eiichiro Amano; Shinichi Otsu
Journal:  BMC Infect Dis       Date:  2018-07-06       Impact factor: 3.090

Review 7.  The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy.

Authors:  Cari Stek; Brian Allwood; Naomi F Walker; Robert J Wilkinson; Lutgarde Lynen; Graeme Meintjes
Journal:  Front Microbiol       Date:  2018-10-30       Impact factor: 5.640

Review 8.  Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease.

Authors:  Carson M Quinn; Victoria Poplin; John Kasibante; Kyle Yuquimpo; Jane Gakuru; Fiona V Cresswell; Nathan C Bahr
Journal:  Life (Basel)       Date:  2020-10-29

Review 9.  Corticosteroids for managing tuberculous meningitis.

Authors:  Kameshwar Prasad; Mamta B Singh; Hannah Ryan
Journal:  Cochrane Database Syst Rev       Date:  2016-04-28

Review 10.  Use of steroids to treat anti-tumor necrosis factor α induced tuberculosis-associated immune reconstitution inflammatory syndrome: Case report and literature review.

Authors:  Daijiro Nabeya; Takeshi Kinjo; Kazutaka Yamaniha; Shoshin Yamazato; Reo Tome; Kazuya Miyagi; Hideta Nakamura; Tetsu Kinjo; Shusaku Haranaga; Futoshi Higa; Jiro Fujita
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.